The World Federation of Hemophilia (WFH) has spearheaded a scientific study updating the prevalence of hemophilia to higher numbers than previously estimated and providing, for...
Enhance your knowledge of emerging gene therapy in hemophilia and claim up to 1.75 AMA PRA Category 1 Credits™ in 2019 with Clinical Advances in...
The Medical Advisory Board of the WFH has published recommendation on the use of Cryoprecipitate for Treatment of Congenital Bleeding Disorders, on 26 April 2019. The recommendations are as follows:...
The WFH is proud to announce that the 1st World Bleeding Disorders Registry (WBDR) Data Report will be published this summer. The WBDR Data Report...
Novo Nordisk announces that the US Food and Drug Administration (FDA) has approved the Biologics License Application for turoctocog alfa pegol, N8-GP, (ESPEROCT)®, a recombinant extended half-life...
In the first of a series of round table meetings, the World Federation of Hemophilia (WFH) Gene Therapy Round Table was convened in April 2018...
On December 6, 2018, MASAC—the NHF’s Medical and Scientific Advisory Council—published recommendation #254, entitled, “MASAC Document Regarding Risks of Gene Therapy Trials for Hemophilia”. MASAC’s recommendation...
On December 6, 2018, MASAC—the NHF’s Medical and Scientific Advisory Council—published recommendation #255 entitled, “Recommendation on the Use and Management of Emicizumab-kxwh (Hemlibra®) for Hemophilia...
The Report on the World Federation of Hemophilia (WFH) Annual Global Survey (AGS) 2017 is now available in print and online at www.wfh.org/globalsurvey. The report includes...
The World Federation of Hemophilia (WFH) is pleased to announce the launch of the fifth and final activity in Clinical Advances in Gene Therapy for...